Relmada Therapeutics, Inc. (RLMD)

Ratios and Metrics (Annual)

Market cap in millions USD. Fiscal year is January - December.

Year	Current	2022	2021	2020	2019	2018	2017	2016	2015
Market Capitalization	90	105	395	521	401	13	10	27	-
Market Cap Growth	-	-73.40%	-24.17%	29.98%	3061.80%	28.38%	-63.97%	-	-
Enterprise Value	-24	-43	183	404	284	13	8	19	-22
PE Ratio	-0.57	-0.67	-3.14	-8.76	-26.71	-1.41	-1.57	-9.21	-
PB Ratio	0.85	0.75	1.90	4.93	3.46	-2.30	6.76	3.89	-
P/FCF Ratio	-0.80	-1.01	-4.30	-18.73	-33.14	-2.11	-1.52	-2.00	-
P/OCF Ratio	-0.80	-1.01	-4.30	-18.73	-33.14	-2.11	-1.53	-2.08	-
EV/EBITDA Ratio	0.34	0.28	-1.46	-6.79	-19.09	-1.76	-1.36	-6.57	1.07
EV/EBIT Ratio	0.34	0.28	-1.46	-6.79	-19.09	-1.75	-1.34	-6.45	1.07
EV/FCF Ratio	0.48	0.42	-1.99	-14.52	-23.52	-2.22	-1.30	-1.40	1.37
Debt / Equity Ratio	-	-	-	-	0.00	-0.53	0.19	0.04	0.03
Debt / EBITDA Ratio	-	-	-	-	-0.01	-0.39	-0.04	-0.09	-0.01
Debt / FCF Ratio	-	-	-	-	-0.01	-0.49	-0.04	-0.02	-0.02
Quick Ratio	11.07	11.94	14.08	9.30	80.04	0.44	1.70	2.85	1.44
Current Ratio	11.40	12.26	14.83	9.37	80.21	0.46	1.80	3.04	1.54
Interest Coverage	-	-	-	-	-143.13	-5.70	-11429.04	-1701.74	-
Return on Equity (ROE)	-94.90%	-88.00%	-107.30%	-50.30%	-46.30%	635.20%	-173.30%	-27.80%	-
Return on Assets (ROA)	-86.30%	-80.40%	-95.10%	-48.20%	-43.30%	-178.90%	-118.90%	-19.80%	-
Return on Capital (ROIC)	-114.10%	-107.60%	-124.30%	-54.40%	-79.40%	312.20%	-25656.00%	113.80%	-
Earnings Yield	-136.04%	-149.50%	-31.84%	-11.41%	-3.74%	-70.70%	-63.68%	-10.86%	-
FCF Yield	-97.59%	-98.82%	-23.26%	-5.34%	-3.02%	-47.45%	-66.00%	-50.02%	-
Buyback Yield / Dilution	-0.55%	-68.80%	-12.56%	-68.75%	-194.65%	-3.90%	-4.10%	-16.68%	-
Total Shareholder Return	-0.55%	-68.80%	-12.56%	-68.75%	-194.65%	-3.90%	-4.10%	-16.68%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).